An interventional study of oral steroid-dexamethasone and non cultured epidermal suspension in Vitiligo, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Vitiligo by Cairo University — 7 open to participants now, 7 under way, 1 of them phase 3. Vitiligo · Cairo University.
Among the 24 studies in Vitiligo by Cairo University, this one is the 5th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 with no phase, and was the 17th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →7 of the 24 studies in Vitiligo by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 6+
Cairo University · Sites in Egypt
Ages 25–40
Cairo University · Sites in Egypt
Ages 18+ · Healthy volunteers
Cairo University · Sites in Egypt
Ages 12+
Cairo University
Ages 18–60
By country, each count listing its studies:
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 30 across the 18 interventional studies, 87 across the 6 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,952 studies on the registry; 1,463 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
1 of the studies in Vitiligo by Cairo University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07595705Cairo UniversityGingival Hyperpigmentation Treatment | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Vitiligo by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assessing the additive value of mini-oral pulse steroid therapy in surgical treatment of acral and difficult to treat sites of vitiligo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
this group will receive oral mini-pulse steroids (low-dose dexamethasone: 5mg/week on 2 successive days per week) for 2 weeks prior to NCES and for 4 weeks afterwards
Drug: oral steroid-dexamethasone · Procedure: non cultured epidermal suspension
this group will undergo None cultured epidermal suspension (NCES) without oral mini-pulse steroids.
Procedure: non cultured epidermal suspension
this study is the first according to the best of our knowledge assessing the value of adding mini oral pulse steroid therapy to non cultured epidermal suspension in treatment of stable acral and difficult to treat vitiligo
this is the best surgical technique for surgical treatment of vitiligo that would be done for both arms
comparing percent change in pigmentation in both arms
• Comparing percent change of pigmentation as per VESTA score after 3 months of treatment with NCES with and without mini oral pulse steroids.
Time frame: 3 months
comparing percent change in surface area in both arms
• Comparing percent change in the surface area of the depigmented patch following NCES using point counting technique.
Time frame: 3 months
comparing physician global assessment in both arms
• Comparing physician global assessment after treatment with NCES with and without oral mini-pulse therapy
Time frame: 3 months
Plan to share: Yes — Participants' data that underlie reported results will be shared upon request, after deidentification
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: within 3 months and for 12 months after completion of the study
Access criteria: Controlled Access: Researchers who provide a methodologically sound proposal will be allowed to access data to achieve aims in the approved proposal
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for Aug 2025, 3 months later.
Of 63 non-industry interventional studies with no phase under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 3 months is below that.
Counting every sponsor, half of 67 studies reached it within 17 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.